Q-omics provides the consensus-scored CICP17 profile across patient tissues and cancer cell-line models. CICP17 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CICP17 is differentially expressed in 2, with the highest sampling consensus in CHOL. Additionally, CICP17 RNA expression shows 6,395 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRC, CHOL, and STAD as cancer lineages where CICP17 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CICP17 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CICP17 survival associations across molecular data types. CICP17 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CICP17 RNA expression–survival associations across cancer types. High CICP17 expression shows unfavorable associations in KIRC, KICH, STAD, DLBC and ACC, but favorable associations in BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for CICP17 RNA expression.
This table summarizes CICP17 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in CHOL for RNA.
This table ranks reproducible tumor–normal expression differences for CICP17. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CICP17 shows higher tumor expression in CHOL and KIRC. The CHOL box plot shows higher CICP17 RNA expression in tumor versus normal tissue (log2 FC = +0.017, t-test p = .022).
This table shows molecular features associated with CICP17 in patient tissues and cancer cell lines. In patient samples, CICP17 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
